4.5 Article

Concise Health Risk Tracking Scale: A Brief Self-Report and Clinician Rating of Suicidal Risk

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 72, Issue 6, Pages 757-764

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m06837

Keywords

-

Funding

  1. Bristol-Myers Squibb
  2. Cephalon
  3. Corcept Therapeutics
  4. Cyberonics
  5. Eli Lilly
  6. Forest
  7. GlaxoSmithKline
  8. Janssen
  9. Merck
  10. National Institute of Mental Health (NIMH) [N01MH90003]
  11. National Alliance for Research in Schizophrenia and Depression (NARSAD)
  12. Novartis
  13. Pfizer
  14. Pharmacia Upjohn
  15. Predix
  16. Solvay
  17. Wyeth-Ayerst
  18. Abbott
  19. Alkermes
  20. Aspect Medical Systems
  21. AstraZeneca
  22. BioResearch
  23. BrainCells
  24. CeNeRx BioPharma
  25. Clinical Trials Solutions
  26. Clintara
  27. Covidien
  28. EnVivo Pharmaceuticals
  29. Euthymics Bioscience
  30. Ganeden Biotech
  31. Icon Clinical Research
  32. i3 Innovus/Ingenix
  33. Johnson & Johnson Pharmaceutical Research Development
  34. Lichtwer Pharma GmbH
  35. Lorex
  36. National Center for Complementary and Alternative Medicine
  37. National Institute of Drug Abuse (NIDA)
  38. Novartis AG
  39. Organon
  40. PamLab
  41. Pharmavite
  42. Photothera
  43. Roche
  44. RCT Logic
  45. Sanofi-Aventis
  46. Shire
  47. Synthelabo
  48. Northwestern Memorial Hospital Women's Board
  49. Evergreen Invitational Award
  50. Educational Foundation of America
  51. American Foundation of Suicide Prevention
  52. Brain Research Foundation
  53. American Psychological Association
  54. Agency for Healthcare Research and Quality
  55. Wyss Institute for Biologically Inspired Engineering
  56. Robert Wood Johnson Foundation
  57. M-3 Corporation
  58. Ovation
  59. Stanley Medical Research Institute
  60. Magstim
  61. Advanced Neuromodulation Systems
  62. Veterans Affairs Cooperative Studies Program
  63. American Foundation for Suicide Prevention
  64. Best Practice Project Management
  65. Brain Resource
  66. Bristol-Myers Squibb/Otsuka
  67. Gerson Lehrman Group
  68. Jazz
  69. Magellan Health Services
  70. Neuronetics
  71. Ono
  72. Otsuka
  73. University of Michigan
  74. Transcept
  75. Urban Institute

Ask authors/readers for more resources

Objective: Monitoring suicidality and risk following initiation of antidepressant treatment is an essential component of clinical care, but few brief, reliable ratings of suicidal ideation and behavior in adults are available. This report evaluates the psychometric properties of a brief self- and clinician-rated measure of factors related to the risk of suicide attempt or completion. Method: Adult outpatients with nonpsychotic major depressive disorder (MDD) (n =240) were enrolled from July 2007 through February 2008 and treated in an 8-week, open-label trial with the clinician's choice of a selective serotonin reuptake inhibitor at 6 primary care and 9 psychiatric clinical care settings in the National Institute of Mental Health-funded Depression Trials Network. Diagnosis of MDD was determined by the Psychiatric Diagnostic Screening Questionnaire and an MDD checklist based on DSM-IV-TR criteria. Suicidal ideation and behavior are 1 of 9 symptoms of MDD (depressed mood, loss of interest, appetite or weight change, sleep disturbance, reduced concentration or indecisiveness, fatigue or decreased energy, psychomotor agitation or retardation, feelings of worthlessness, or excessive guilt). The newly developed Concise Health Risk Tracking (CHRT) scale was administered both as the CHRT Self-Report (CHRT-SR) and Clinician Rating (CHRT-C) scales. Psychometric evaluations were conducted on both scales. Results: The internal consistency (Cronbach alpha) was .77 for the 7-item CHRT-C and .78 for the 7-item CHRT-SR with a consistent factor structure, and 3 independent factors (current suicidal thoughts and plans, perceived lack of social support, and hopelessness) for both versions. Conclusions: The 7-item CHRT-C and the 7-item CHRT-SR have excellent psychometric properties and can be used to monitor suicidal risk in clinical practice and research settings. Whether either scale will predict suicide attempts or completions in actual practice would require a very large prospective study sample.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available